Patents by Inventor Peter Senter

Peter Senter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11510959
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: November 29, 2022
    Assignee: Seagen Inc.
    Inventors: Svetlana Doronina, Robert Lyon, Peter Senter
  • Patent number: 11230610
    Abstract: The invention provides bivalent antibodies including two light and heavy chain pairs. The N-termini of one or both light and heavy chain pairs are linked via linkers comprising a protease cleavage site to coiled-coil forming peptides that associate to form a coiled coil reducing binding affinity of at least one light-heavy chain pair to a target.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: January 25, 2022
    Assignee: SEAGEN INC.
    Inventors: Vivian Trang, Matthew R. Levengood, Peter Senter
  • Publication number: 20210283210
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Application
    Filed: January 27, 2021
    Publication date: September 16, 2021
    Inventors: Svetlana DORONINA, Robert LYON, Peter SENTER
  • Publication number: 20210260086
    Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 26, 2021
    Inventors: Peter SENTER, Stephen ALLEY, Dennis BENJAMIN
  • Patent number: 11033561
    Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 15, 2021
    Assignee: SEAGEN INC.
    Inventors: Peter Senter, Stephen Alley, Dennis Benjamin
  • Publication number: 20210138077
    Abstract: The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.
    Type: Application
    Filed: September 18, 2020
    Publication date: May 13, 2021
    Inventors: Noah BINDMAN, Nicole OKELEY, Peter SENTER, Divya AWASTHI
  • Patent number: 10933112
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 2, 2021
    Assignee: SEAGEN INC.
    Inventors: Svetlana Doronina, Robert Lyon, Peter Senter
  • Publication number: 20200061091
    Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
    Type: Application
    Filed: June 25, 2019
    Publication date: February 27, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Peter Senter, Stephen Alley, Dennis Benjamin
  • Patent number: 10561739
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: February 18, 2020
    Assignees: SEATTLE GENETICS INC., MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
  • Publication number: 20190352428
    Abstract: The invention provides bivalent antibodies including two light and heavy chain pairs. The N-termini of one or both light and heavy chain pairs are linked via linkers comprising a protease cleavage site to coiled-coil forming peptides that associate to form a coiled coil reducing binding affinity of at least one light-heavy chain pair to a target.
    Type: Application
    Filed: December 8, 2017
    Publication date: November 21, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Vivian TRANG, Matthew R. LEVENGOOD, Peter SENTER
  • Publication number: 20190336614
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Application
    Filed: April 11, 2019
    Publication date: November 7, 2019
    Inventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
  • Patent number: 10342811
    Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: July 9, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter Senter, Stephen Alley, Dennis Benjamin
  • Publication number: 20180353524
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an effective amount of 2-deoxy-2-fluoro-L-fucose or a prodrug thereof, or a pharmaceutically acceptable salt thereof, in combination with a checkpoint inhibitor.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 13, 2018
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Shyra Gardai, Che-Leung Law, Peter Senter, Nicole Okeley, Jessica Field
  • Publication number: 20180228916
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Application
    Filed: April 12, 2018
    Publication date: August 16, 2018
    Inventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
  • Patent number: 9732084
    Abstract: Pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position on one monomer unit, and a C2-C3 double bond and either a conjugated double or triple bond at the C2 position or an alkyl group at the C2 position on the other monomer unit, and conjugates of these compounds.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 15, 2017
    Assignees: Medimmune Limited, Seattle Genetics Inc.
    Inventors: Philip Wilson Howard, Luke Masterson, Arnaud Tiberghien, Scott Jeffrey, Patrick Burke, Peter Senter
  • Publication number: 20170216391
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Application
    Filed: February 17, 2015
    Publication date: August 3, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana Doronina, Robert Lyon, Peter Senter
  • Publication number: 20170143846
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Application
    Filed: February 1, 2017
    Publication date: May 25, 2017
    Inventors: Philip Wilson HOWARD, Scott JEFFREY, Patrick BURKE, Peter SENTER
  • Patent number: 9592240
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: March 14, 2017
    Assignees: SEATTLE GENETICS INC., MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
  • Publication number: 20170035790
    Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
    Type: Application
    Filed: October 21, 2016
    Publication date: February 9, 2017
    Applicant: Seattle Genetics, Inc.
    Inventors: Peter Senter, Stephen Alley, Dennis Benjamin
  • Patent number: 9504702
    Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: November 29, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter Senter, Stephen Alley, Dennis Benjamin